| Combination of | |
|---|---|
| DTaP vaccine | Vaccine |
| Hib vaccine | Vaccine |
| Clinical data | |
| Trade names | TriHIBit, ActHIB with Tripedia |
| Routes of administration | Intramuscular injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
DTaP-Hib vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed with Haemophilus B conjugate vaccine, sometimes abbreviated to DTaP-Hib.[1] It protects against the infectious diseases diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.
A branded formulation was marketed in the US as TriHIBit by Sanofi Pasteur, and administered by using the Sanofi DTaP vaccine Tripedia to reconstitute the Sanofi Hib vaccine ActHIB.[2][3][4] TriHIBit and Tripedia were discontinued in 2011.[5] The current Sanofi DTaP formulation is Daptacel.
References
- ↑ "Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) Disease Interactions". Drugs.com. Retrieved 15 July 2018.
- ↑ "Notice to Readers FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution with an Acellular Pertussis Vaccine". Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. 15 November 1996. pp. 993–995. Retrieved 15 July 2018.
- ↑ "Tripedia package insert" (PDF). US Food and Drug Administration. Archived from the original (PDF) on 12 January 2017. Retrieved 15 July 2018.
- ↑ "ActHIB package insert" (PDF). US Food and Drug Administration. Retrieved 15 July 2018.
- ↑ "Selected Discontinued U.S. Vaccines" (PDF). Centers for Disease Control and Prevention. Retrieved 15 July 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.